Weight-related care
Weight care has product-specific answers
A weight-related care discussion needs a named medicine and a reason for using it. Knowing it comes as an injection still leaves questions about the plan.
The medicine and its use belong together
At the September 2026 check, semaglutide (Ozempic, Wegovy) had US approvals for products in tablet and injection form.
That record includes weight treatment with Wegovy, used with eating and activity changes.
The record also includes tirzepatide (Mounjaro, Zepbound), with Zepbound approved for long-term weight care.
What if a pharmacy offers to mix its own version?
A pharmacist or doctor can mix or change the ingredients in a medicine for a patient. This is called compounding.
A generic version of a brand-name drug goes through drug approval. A pharmacy’s mixture has not passed through that process.
The September 2026 check found no generic of semaglutide or tirzepatide approved for US sale.
Liraglutide is a different drug from semaglutide and tirzepatide. Some of its generic versions had approval for weight loss at the September 2026 check.
A national shortage means supplies of a drug are low. The law can then allow pharmacies to prepare copies of an approved medicine.
The September 2026 shortage check found neither semaglutide injection nor tirzepatide listed. That reason for making copies no longer applied.
For approved medicines already on sale, rules limit the making of copies. The prescriber decides whether a change for that named patient makes a significant difference. Such a change can mean the pharmacy’s preparation is not counted as a copy under this restriction. Paying less is not enough to meet this test.
For example, someone allergic to the colouring in a ready-made medicine may need that ingredient changed.